Smallpox vaccine: Problems and prospects

Immunology and Allergy Clinics of North America

Volumn 23, Issue 4, 2003, Pages 731-743

  Poland, Gregory A ^a   Neff, John M ^b  

^a MAYO CLINIC   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYNPORT; LIVE VACCINE; PEPTIDE; SMALLPOX VACCINE;

CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ECZEMA; ECZEMA VACCINATUM; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; INFECTION SENSITIVITY; MORBIDITY; MORTALITY; MYOPERICARDITIS; NECROSIS; PERICARDITIS; POSTVACCINAL ENCEPHALITIS; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSIVE VACCINATUM; PUBLIC HEALTH SERVICE; REVIEW; SCREENING; SIDE EFFECT; SMALLPOX; VACCINATION REACTION; VACCINIA GANGRENOSA; VACCINIA VIRUS; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 0346965789     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8561(03)00096-1     Document Type: Review

References (59)

1. World Health Organization. Declaration of global eradication of smallpox. Wkly Epidemiol Rec 1980;55:148.
2. Henderson DA. The looming threat of bioterrorism. Science 1999;283:1279-82.
3. Bartlett J, Borio L, Radonovich L, Mair JS, O'Toole T, Mair M, et al. Smallpox vaccination in 2003: key information for clinicians. Clin Infect Dis 2003;36:883-902.
4. Bicknell WJ. The case for voluntary smallpox vaccination. N Engl J Med 2002;346:1323-5.
5. Bozzette SA, Boer R, Bhyatnagar V, Brower JL, Keeler EB, Morton SC, et al. A model for a smallpox-vaccination policy. N Engl J Med 2003;348:416-25.
6. Breman JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med 2002;346: 1300-8.
7. Henderson DA. Smallpox: clinical and epidemiologic features. Emerg Infect Dis 1999;5:537-9.
8. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, et al. Smallpox as a biological weapon: medical and public health management. JAMA 1999;281:2127-37.
9. Centers for Disease Control and Prevention. Vaccinia (smallpox) vaccine: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1991; 40:1-10.
10. US Food and Drug Administration, Department of Health and Human Services. Product approval information-licensing information. Available at: http://www.fda.gov/cber/approvltr/smalwye102502L.htm. Accessed June 2003.
11. Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK, et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002;346:1265-74.
12. Newman FK, Frey SE, Blevins TP, Yan L, Belshe RB. Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax. J Infect Dis 2003;187:1319-22.
13. Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, Paoletti E. The complete DNA sequence of vaccinia virus. Virology 1990;179:247-66.
14. McClain DJ, Harrison S, Yeager CL, Cruz J, Ennis FA, Gibbs P, et al. Immunologic responses to vaccinia vaccines administered by different parenteral routes. J Infect Dis 1997;175: 756-63.
15. Available at: http://www.bt.cdc.gov/agent/smallpox/vaccination/heartproblems-vis.asp. Accessed June 2003.
16. Moller-Larsen A, Haahr S. Humoral and cell-mediated immune responses in humans before and after revaccination with vaccinia virus. Infect Immun 1978;19:34-9.
17. Sarkar JK, Mitra AC, Mukherjee MK. The minimum protective level of antibodies in smallpox. Bull World Health Organ 1975;52:307-11.
18. Frey SE, Newman FK, Cruz J, Shelton B, Tennant JM, Polach T, et al. Dose-related effects of smallpox vaccine. N Engl J Med 2002;346:1275-80.
19. Perrin LH, Zinkernagel RM, Oldstone MB. Immune response in humans after vaccination with vaccinia virus: generation of a virus-specific cytotoxic activity by human peripheral lymphocytes. J Exp Med 1977;146:949-69.
20. + cytotoxic T lymphocytes and interferon-γ-producing T cells after smallpox vaccination. J Infect Dis 2002;185:1657-9.
21. + cytotoxic T lymphocytes in humans. J Virol 1993;67:1538-44.
22. Terajima M, Cruz J, Raines G, Kilpatrick ED, Kennedy JS, Rothman AL, et al. Quantitation of CD8+ T cell responses to newly identified HLA-A * 0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med 2003;197:927-32.
23. Drexler I, Staib C, Kastenmüller W, Stevanovic S, Schmidt B, Lemonnier FA, et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A 2003;100:217-22.
24. Demkowicz Jr WE, Littaua RA, Wang J, Ennis FA. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 1996;70:2627-31.
25. Advisory Committee on Immunization Practices. Vaccinia (smallpox) vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Morb Mortal Wkly Rep 2001;50:1-22.
26. Mortimer PP. Can postexposure vaccination against smallpox succeed? Clin Infect Dis 2003;36: 622-9.
27. Arita I. Duration of immunity after smallpox vaccination: a study on vaccination policy against smallpox bioterrorism in Japan. Jpn J Infect Dis 2002;55:112-6.
28. Sauri M, Sibley C, Monk B, Nichols M, Lai S. Durability of vaccinia immunization based on reaction at the rechallenge site. Md Med 2002;3:44-51.
29. Hanna W, Baxby D. Studies in smallpox and vaccination, 1913. Rev Med Virol 2002;12:201-9.
30. El-Ad B, Roth Y, Winder A, Tochner Z, Lublin-Tennenbaum T, Katz E, et al. The persistence of neutralizing antibodies after revaccination agaainst smallpox. J Infect Dis 1990;161:446-8.
31. Mack TM. Smallpox in Europe, 1950-1971. J Infect Dis 1972;125:161-9.
32. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969;281:1201-8.
33. Centers for Disease Control Prevention. Update: adverse events following civilian smallpox vaccination-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:475-7.
34. Neff JM, Lane JM, Pert JH, Moore R, Millar JD, Henderson DA. Complications of smallpox vaccination. 1. National survey in the United States, 1963. N Engl J Med 1967;276:125-32.
35. Neff JM, Levine RH, Lane JM, Ager EA, Moore H, Rosenstein BJ, et al. Complications of smallpox vaccination United States 1963. II. Results obtained by four statewide surveys. Pediatrics 1967;39:916-23.
36. Neff JM, Drachman RH. Complications of smallpox vaccination, 1968 surveillance in a comprehensive care clinic. Pediatrics 1972;50:481-3.
37. Lane JM, Ruben FL, Abrutyn E, Millar JD. Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968. JAMA 1970;212:441-4.
38. Grabenstein JD, Winkenwerder Jr W. US military smallpox vaccination program experience. JAMA 2003;289:3278-82.
39. Centers for Disease Control and Prevention. Update: adverse events following civilian smallpox vaccination-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:819-20.
40. Centers for Disease Control and Prevention. Smallpox (vaccinia) vaccine contraindications. Available at: http://www.bt.cdc.gov/agent/smallpox/vaccination/contraindications-clinic.asp. Accessed June 2003.
41. Kempe CH. Studies on smallpox and complications of smallpox vaccination. Pediatrics 1960; 26:176-89.
42. Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 1975;55:342-7.
43. Neff JM, Lane JM, Fulginiti VA, Henderson DA. Contact vaccinia-transmission of vaccinia from smallpox vaccination. JAMA 2002;288:1901-5.
44. Schultz LF, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2002;22:1-24.
45. Engler RJM, Kenner J, Leung DYM. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J Allergy Clin Immunol 2002;110:357-65.
46. Sepkowitz KA. How contagious is vaccinia? N Engl J Med 2003;348:439-46.
47. Horwitz MS, Solomon P. A family epidemic of vaccinia. J Pediatr 1966;68:308-10.
48. Centers for Disease Control and Prevention. Contact spread of vaccinia from a recently vaccinated marine-Louisiana. MMWR Morb Mortal Wkly Rep 1984;33:37-8.
49. Centers for Disease Control and Prevention. Vaccinia outbreak-Newfoundland. MMWR Morb Mortal Wkly Rep 2003;30:453-5.
50. Gray FG. A familial spread of vaccinia with one death: isolation and identification of the virus. Bull Johns Hopkins Hosp 1947;83:538-49.
51. Centers for Disease Control and Prevention. Smallpox vaccine and monkeypox. Available at: http://www.cdc.gov/ncidod/monkeypox/smallpoxvaccine_mpox.htm. Accessed June 2003.
52. Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003;289: 3283-9.
53. Centers for Disease Control and Prevention. Women with smallpox vaccine exposure during pregnancy reported to the National Smallpox Vaccine in Pregnancy Registry-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:386-8.
54. Bartlett JG. Smallpox vaccination and patients with human immunodeficiency virus infection or acquired immunodeficiency syndrome. Clin Infect Dis 2003;36:468-71.
55. Centers for Disease Control and Prevention. Medical management of smallpox (vaccinia) vaccine adverse reactions: vaccinia immune globulin and cidofovir. Available at: http://www.bt.cdc.gov/agent/smallpox/vaccination/mgmt-adv-reactions.asp. Accessed June 2003.
56. Bonilla-Guerrero R, Poland GA. Smallpox vaccines: current and future. J Clin Med, in press.
57. Poland GA, Ovsyannikova IG, Johnson KL, Naylor S. The role of mass spectrometry in vaccine development. Vaccine 2001;19:2692-700.
58. Altenburger W, Suter CP, Altenburger J. Partial deletion of the human host range gene in the attenuated vaccinia virus MVA. Arch Virol 1989;105:15-27.
59. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998;79:1159-67.